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Abstract
Determining the sample size of an experiment can be challenging, even more so when incorporating
external information via a prior distribution. Such information is increasingly used to reduce the size
of the control group in randomized clinical trials. Knowing the amount of prior information, expressed
as an equivalent prior effective sample size (ESS), clearly facilitates trial designs. Various methods to
obtain a prior’s ESS have been proposed recently. They have been justified by the fact that they give
the standard ESS for one-parameter exponential families. However, despite being based on similar
information-based metrics, they may lead to surprisingly different ESS for non-conjugate settings,
which complicates many designs with prior information. We show that current methods fail a basic
predictive consistency criterion, which requires the expected posterior–predictive ESS for a sample of
size N to be the sum of the prior ESS and N . The expected local-information-ratio ESS is introduced
and shown to be predictively consistent. It corrects the ESS of current methods, as shown for normally
distributed data with a heavy-tailed Student-t prior and exponential data with a generalized Gamma
prior. Finally, two applications are discussed: the prior ESS for the control group derived from
historical data, and the posterior ESS for hierarchical subgroup analyses.
Keywords: co-data, Fisher information, historical data, meta-analytic-predictive prior distribution,
prior predictive distribution
1 Introduction
Sample sizes are an integral part of clinical trial designs and usually follow from error rate (type-I, power)
or precision requirements. Such sample size determinations are standard if no trial-external information
is formally included in the analysis of the parameter of interest.
If trial-external information contributes to the inference, one would ideally want to quantify it via
an equivalent effective sample size (ESS). Yet this can be difficult. For example, if historical control
data inform the prior distribution for the response rate of the control group in a randomized trial, the
amount of prior information is not simply the number of historical control subjects. It must be less due
to between-trial heterogeneity, which is unknown.
In health-care applications, additional data (or co-data, Neuenschwander, Roychoudhury, Schmidli
(2016)) are increasingly valued. In addition to the above example, applications include medical device trials
(FDA (2010)), non-inferiority trials with historical or even concurrent placebo (FDA (2010)), pediatric
trials with adult data (FDA (2004), Goodman and Sladky (2005)), health-technology assessments (Dias,
Welton, Sutton, Ades (2011), Spiegelhalter, Abrams, Myles (2004)), pharmacometrics (Demin, Hamren,
Luttringer, Pillai et al. (2012), Nedelman, Bretz, Fisch, Georgieva et al. (2010)), and bridging studies.
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In Section 2 we will review the standard ESS for the one-parameter exponential family, discuss
current methods for non-conjugate settings (Malec (2001), Morita, Thall, Mu¨ller (2008), Neuenschwan-
der, Capkun-Niggli, Spiegelhalter (2010), Pennello and Thompson (2008)), introduce the expected local-
information ratio ESSELIR as an alternative, investigate the different ESS for two examples, and show
that only ESSELIR is predictively consistent. In Section 3, prior and posterior ESSELIR will be discussed
in the context of two recent phase II trials.
2 Methodology
In this Section, we aim to quantify the information for the parameter θ of a statistical model f(Y |θ),
expressed as an equivalent effective sample size (ESS). The information about θ is given probabilistically
as a prior (or posterior) distribution p(θ). The discussion will be restricted to one-dimensional parameters.
2.1 Effective sample sizes under conjugacy
Prior effective sample sizes are well understood for conjugate one-parameter exponential families, such as:
normal data with mean µ (and known variance s2) and a normal prior with variance s2/n0 (ESS = n0);
binary data with response probability θ and a Beta(a, b) prior (ESS = a + b); and, Poisson data with
mean (hazard) θ and a Gamma(a, b) prior (ESS = b).
These ESS can be motivated in various ways. First, in the updating rule from prior to posterior
parameters, the sample size n appears explicitly, suggesting a corresponding prior ESS. For example, for
Poisson data with a Gamma(a, b) prior, the second parameter of the posterior Gamma distribution is b+n,
implying b as the prior ESS.
Second, the posterior mean is a weighted average of the prior mean and the standard parameter
estimate, with weights proportional to the prior ESS and the sample size n. Again, for Poisson data, the
prior mean and parameter estimate are a/b and
∑
Yj/n, and the posterior mean (a +
∑
Yj)/(b + n) is
the weighted average of the two, with weights proportional to b and n. Of note, for exponential data with
mean µ and an inverse-Gamma(a, b) prior, however, the ESS for the weighted-mean approach is a − 1
(a > 1), slightly different from the above updating-rule ESS=a. Moreover, for exponential data with
censoring, ESS refers to the effective number of events rather than number of observations.
2.2 Variance- and precision-ratio methods
A third, information-based justification is less well-known but will serve as a basis for approaches to ESS
beyond conjugacy. It relates the variance (or precision) of the prior to the variance of an estimator YN for
θ from a sample of size N . The ESS is then the N for which the two variances are the same. Since the
variance of YN will usually depend on θ, the expected variance under p(θ) is taken instead, which leads to
ESS =
N Eθ{Var(YN |θ)}
Var(θ)
(1)
It can be shown that (1) gives the standard ESS for the main one-parameter exponential families. In the
sequel, we will use a small modification, which will be needed for the ESS of Sections 2.3 and 2.4. Letting
iF (θ) and iF (Y1; θ) be the expected and observed Fisher information for one information unit,
iF (θ) = EY1|θ {iF (Y1; θ)} = −EY1|θ
{
d2 log f(Y1|θ)
dθ2
}
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the variance-ratio and precision-ratio ESS are defined as
ESSV R =
Eθ{i−1F (θ)}
Var(θ)
, ESSPR =
Var−1(θ)
Eθ{iF (θ)} (2)
ESSV R and ESSPR are equal or close to the standard ESS for the main one-parameter exponential
families. For example, for Poisson data and a Gamma(a, b) prior, Var(θ) = a/b2, iF (θ) = 1/θ, E{i−1F (θ)} =
a/b, and ESSV R = b. On the other hand, E{iF (θ)} = b/(a− 1), and ESSPR = b(a− 1)/a, which will be
close to b except for very small a.
In the sequel, we will use ESSV R and ESSPR in (2) to represent the variance-ratio and precison-ratio
methods. However, other variance-ratio methods have been suggested by Malec (2001), Neuenschwander
et al. (2010), and Pennello and Thompson (2008). They obtain the ESS of a prior by relating its variance
to the variance from an analysis for which the ESS is known. We do not include these proposals in the
following comparisons because they are similar to ESSV R and ESSPR.
2.3 The Morita-Thall-Mu¨ller (MTM) method
Another, more involved information-based ESS has been suggested in the seminal paper by Morita et al.
(2008). In addition to the Fisher information, it uses the information of the prior distribution p(θ)
i(p(θ)) = −d
2 log p(θ)
dθ2
(3)
and the information of an -information (large-variance) prior p0(θ) with the same mean (θ) as p(θ)
i(p0(θ)) = −d
2 log p0(θ)
dθ2
The authors then define the ESS as the integer m that minimizes
|i(p0(θ)) + EYm{iF (Ym; θ)} − i(p(θ))| (4)
Here, the expectation of Ym is taken over the prior-predictive distribution under p(θ). (4) is the distance
(evaluated at the prior mean θ) between the expected posterior information for a sample of size m based
on the same-mean-large-variance prior p0(θ) (the first two terms) and the information of the actual prior
(third term).
The approach is noteworthy because it appears to be the first formal, metric-based approach to ESS
that complies with the standard one-parameter exponential family ESS. Some points deserve attention:
(i) Evaluating the distance (4) at the mode may appear more natural. However, as the authors point
out, only with the mean one obtains the one-parameter exponential family ESS.
(ii) The choice of the “same-mean-large-variance prior” p0(θ) is not unique. Yet, since the prior p0(θ)
carries very little information, one would expect the consequences to be minor. For example, for
Poisson data with hazard θ, conjugate Gamma(a, b) prior, and p0(θ) chosen as log-normal(m0, s
2
0),
the following holds: θ = a/b = exp(m0 + s
2
0/2), and for m0 = log(θ) − s20/2 and increasing s0,
i(p0(θ))→ −1.5/θ2. This implies ESSMTM = (a− 1)/θ + 1.5/θ = b(1 + 0.5/a). The increase from
the standard ESS = b will be small except for very small a.
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(iii) Restricting m to integers seems not important; one may minimize the distance (4) over continuous m
and then round to integers. Setting (4) to zero and noting that EYm{iF (Ym; θ)} = m·EY1{iF (Y1; θ)},
it follows that
ESSMTM =
i(p(θ))− i(p0(θ))
EY1{iF (Y1; θ)}
(5)
Moreover, since p0(θ) is not unique and really only needed to nudge the computation of the expected
Bayesian posterior information with an “uninformative prior”, a simplified version that ignores this
prior could be used. Additionally approximating the expected posterior information by m · iF (θ)
and using the prior mode θ˜ instead of the prior mean θ leads to the ESS suggested by Pennello and
Thompson (2008)
ESSMTM.P =
i(p(θ˜))
iF (θ˜)
(6)
which will usually be easier to compute than (5).
Finally, (5) and (6) appear similar to the precision-ratio ESS (2). That these similarities can be illusory
will be shown in Section 2.5.
2.4 The expected local-information-ratio (ELIR) ESS
We propose yet another information-based ESS, which will be shown to be superior to current versions.
The expected local-information-ratio (ELIR) method also uses the prior and Fisher information. However,
instead of locally evaluating the respective information ratio at the mean (or mode), it is defined as the
mean of the prior information to Fisher information ratio r(θ)
ESSELIR = Eθ{r(θ)} = Eθ
{
i(p(θ))
iF (θ)
}
(7)
First, and importantly, ESSELIR gives the well-known effective sample sizes for some standard one-
parameter exponential families. In Table 1, the main quantities and ESSELIR are shown for the mean
parameter as well as the natural parameter.
For the natural parameter η, ESSELIR is the standard ESS without any boundary restriction on the
parameters. Here, the information ratio r(η) = i(p(η))/iF (η) does not depend on the parameter. For the
natural parameter, the sampling and prior distribution can be written as
f(y|η) = exp{yη −M(η)}, p(η) = exp{n0m0η − n0M(η)}
Since iF (η) = d
2M(η)/dη2, it follows that ESSELIR = n0. For example, for binary data with a Beta(a, b)
prior for the mean µ, η = log{µ/(1−µ)}, M(η) = log{1 + exp(η)}, and n0 = a+ b. For Poisson data with
a Gamma prior for the mean µ, η = log(µ), M(η) = exp(η), and n0 = b.
While the standard effective sample sizes are obtained for the natural parameter, some special cases
arise for vague priors of the mean parameter µ (Table 1). For example, for binary data with a Beta(a,b)
prior, ESS = a+b is only obtained for a > 1, b > 1. If one of the parameters is less than 1, ESSELIR is not
defined because the expectation of the local information ratio r(µ) = (a−1)(1−µ)/µ+(b−1)µ/(1−µ) does
not exist; for the uniform distribution (a = b = 1), ESSELIR = 0; and, finally a = 1, b > 1 (or a > 1, b = 1)
leads somewhat suprisingly to ESSELIR = 1, since (for the former) ESSELIR = (b− 1)Eµ{µ/(1− µ)} =
(b− 1)a/(b− 1) = a = 1.
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Table 1: Prior information i(p(µ)) and i(p(η)), Fisher unit information iF (µ) and iF (η), local-information ratio
r(µ) and r(η), and expected local-information-ratio ESSELIR for some one-parameter exponential families: µ
and η are the mean and natural parameter, respectively.
parameter i(p(µ)), i(p(η)) iF (µ), iF (η) r(µ), r(η) ESSELIR
Normal (σ known): Y ∼ N(µ, σ2), µ ∼ N(m0, s20)
µ s−20 σ
−2 σ2/s20 σ
2/s20
Binomial: Y ∼ Bin(µ, 1), µ ∼ Beta(a, b), η = logit(µ)
µ (a− 1)/µ2 + (b− 1)/(1− µ)2 1/µ+ 1/(1− µ) (a− 1)(1− µ)/µ+ (b− 1)µ/(1− µ) a+ b (a, b > 1)
η (a+ b) exp(η)/(1 + exp(η))2 exp(η)/(1 + exp(η))2 a+ b a+ b
Poisson: Y ∼ Pois(µ), µ ∼ Ga(a, b), η = log(µ)
µ (a− 1)/µ2 1/µ (a− 1)/µ b (a > 1)
η b exp(η) exp(η) b b
Exponential: Y ∼ Exp(1/µ), µ ∼ Inv-Ga(a, b), η = 1/µ
µ −(a+ 1)/µ2 + 2b/µ3 1/µ2 −(a+ 1) + 2b/µ a− 1
η (a− 1)/η2 1/η2 a− 1 a− 1
Chi-square: s2d ∼ Ga(d/2, d/(2σ2)) σ2 ∼ Inv-Ga(a, b), η = 1/σ2
σ2 −(a+ 1)/σ4 + 2b/σ6 d/(2σ4) −2(a+ 1)/d+ 4b/(2σ2) 2(a− 1)/d
η (a− 1)/η2 d/(2η2) 2(a− 1)/d 2(a− 1)/d
2.5 Examples
We now discuss two examples with non-conjugate prior distributions and show that the ESS for the
methods discussed so far can differ considerably.
2.5.1 Normal data with a Student-t prior
We first assume normal data (with known variance s2) and a Student-t prior with df degrees of freedom for
the mean parameter θ. Such a heavy-tailed prior is robust in the sense that the prior influence decreases
with increasing conflict between the data and the prior (O’Hagan (1979), O’Hagan and Pericchi (2012)).
The Fisher and prior information are
iF (θ) = 1/s
2, i(p(θ)) =
df + 1
df
1− θ2/df
(1 + θ2/df)2
Noting that the prior information for a t-prior with scale s0 is i(p(θ))/s
2
0, the variance-ratio and precision-
ratio ESS are
ESSV R = ESSPR = (s/s0)
2(df − 2)/df (df > 2)
On the other hand, using a large-variance (in the limit improper) prior p0(θ),
ESSMTM = (s/s0)
2(df + 1)/df (df > 1)
and ESSMTM.P = ESSMTM . Finally, intergrating i(p(θ)) over the prior distribution gives
ESSELIR = (s/s0)
2(df + 1)/(df + 3)
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Table 2 (upper part) shows that for small df , the interesting case if robustness is the aim, these ESS differ
considerably. This is problematic when deciding on the size of an experiment that will incorporate prior
information in the analysis. Of note, the above formulas show that with increasing degrees of freedom,
ESS is increasing when using the inverse of the variance (ESSV R, ESSPR) but decreasing when using the
curvature at the mean (ESSMTM ). For ESSELIR, which uses the expected curvature, ESS is increasing.
2.5.2 Exponential data with a generalized Gamma prior
The second example assumes exponentially distributed data, for which the prior of the hazard parameter
θ is a generalized Gamma distribution with shape parameter a, scale parameter s, and family parameter
f . Its density is
p(θ) =
fθa−1 exp{−(θ/s)f )}
saΓ(a/f)
This three-parameter distribution offers more flexibility than the conjugate Gamma distribution and may
thus be useful when representing prior information (for example three quartiles elicited from experts).
It includes Gamma (f = 1) and Weibull (f = a) distributions as special cases. The Fisher and prior
information are
iF (θ) = 1/θ
2, i(p(θ)) = (a− 1)/θ2 + f(f − 1)θf−2/sf
The variance-ratio and precision ratio ESS are
ESSV R = E(θ
2)/Var(θ), ESSPR = E
−1(1/θ2)/Var(θ)
which follow from E(θr) = srΓ{(a+ r)/f}/Γ(a/f); note that ESSPR only exists for a > 2. Further, using
a large-variance Gamma prior for p0(θ),
ESSMTM = a+ f(f − 1) [Γ{(a+ 1)/f}]f /{Γ(a/f)}f
Using the mode θ˜ = s{(a− 1)/f}1/f , the simplified ESSMTM.P is
ESSMTM.P = af − f
Finally, the expected local-information-ratio ESS is
ESSELIR = af − 1
Table 2 (lower part) shows the effective sample sizes for some parameter constellations (including Gamma,
Weibull, and genuine generalized Gamma distributions), which have been grouped by equal ESSELIR
values. The dilemma is the same as in the first example: the ESS can differ considerably, in particular
with increasing amounts of prior information.
2.6 The predictive consistency criterion
So far we have discussed various approaches to ESS, which work well for conjugate settings but can differ
considerably otherwise. To resolve this dilemma, more than fulfilling the exponential family criterion is
needed. We require the ESS to meet the additional predictive consistency criterion:
Predictive consistency: for a sample of size N , the expected
posterior ESS must be the sum of the prior ESS and N .
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Table 2: Prior ESS for various methods: for normal data (known s2 = 100) with Student-t(df) prior, and for
exponential data with generalized Gamma(a,s=1,f) prior.
ESS for normal data with Student-t prior
df VR PR MTM MTM.P ELIR
2 — — 150 150 60
3 33 33 133 133 67
4 50 50 125 125 71
5 60 60 120 120 75
10 80 80 110 110 85
50 96 96 102 102 96
ESS for exponential data with generalized-Gamma prior (a,s=1,f)
distribution a f VR PR MTM MTM.P ELIR
Gamma 9.00 1.00 10.0 6.2 9.0 8.0 8.0
Weibull 3.00 3.00 8.6 3.5 7.3 6.0 8.0
gen-Gamma 2.54 3.54 7.9 2.3 6.4 5.4 8.0
Gamma 25.00 1.00 26 22 25 24 24
Weibull 5.00 5.00 20 15 18 20 24
gen-Gamma 4.52 5.52 19 14 16 19 24
Gamma 49.00 1.00 50 46 49 48 48
Weibull 7.00 7.00 36 32 33 42 48
gen-Gamma 6.52 7.52 35 30 31 41 48
Gamma 81.00 1.00 82 78 81 80 80
Weibull 9.00 9.00 58 53 53 72 80
gen-Gamma 8.51 9.51 55 51 50 71 80
Gamma 121.00 1.00 122 118 121 120 120
Weibull 11.00 11.00 84 79 77 110 120
gen-Gamma 10.51 11.51 81 76 74 109 120
Gamma 169.00 1.00 170 166 169 168 168
Weibull 13.00 13.00 115 110 106 156 168
gen-Gamma 12.51 13.51 111 107 102 155 168
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For some of the examples of Section 2.5, Table 3 shows the difference between the expected posterior
ESS and N , which should be the prior ESS. Only ESSELIR seems to be predictively consistent. It should
be noted that the results are not exact: they represent the mean of 10000 simulations, each generating data
of size N (10,100,1000) from the prior predictive distribution and then obtaining the respective posterior
distribution and its ESS. Interestingly, for large N it seems that the difference of the expected posterior
ESS and N converges to ESSELIR for all methods.
In fact, it can be shown that ESSELIR is predictively consistent for any planned sample size N . The
proof is as follows: let YN be the predictive data of size N with posterior distribution p(θ|YN ), for which
the posterior ESSELIR is
Eθ|YN
{
i(p(θ))− d2 log f(YN |θ)/dθ2
iF (θ)
}
The expected posterior effective sample size under the prior predictive distribution is then
EYN
[
Eθ|YN
{
i(p(θ))− d2 log f(YN |θ)/dθ2
iF (θ)
}]
= Eθ
[
EYN |θ
{
i(p(θ))− d2 log f(YN |θ)/dθ2
iF (θ)
}]
= Eθ
{
i(p(θ)) +NiF (θ)
iF (θ)
}
= ESSELIR +N
2.7 Computations
Computing ESSELIR (7) of a prior analytically was possible in the examples of Section 2.5. For priors
derived from historical data, obtaining ESSELIR analytically will usually not be possible, except for
special cases with known (or assumed) variance components in the hierarchical model or a known power
parameter for power priors (Pocock (1976), Chen and Ibrahim (2000), Neuenschwander, Branson, and
Spiegelhalter (2009)).
If the prior ESS cannot be computed analytically, approximations can be used. First, if the prior
is parametric, the information i(p(θ)) may be available analytically but the expectation (7) may require
numerical integration or simulations from p(θ) to obtain the empirical mean as an estimate of ESSELIR.
A second approximation will be needed if p(θ) is not directly available. For example, p(θ) may be
a large simulation sample (typically from an MCMC analysis); see Section 3 for two such applications.
While inconvenient, this does not pose serious problems because p(θ) can be approximated by a mixture
of standard distributions (e.g., normal, Beta, Gamma) to any degree of accuracy (Dallal and Hall (1983),
Diaconis and Ylvisaker (1984)), and the respective information i(p(θ)) follows from the second derivatives
of the log-mixture distribution (see Appendix).
In this context, it should be noted that the ESS of a mixture distribution is not the respective weighted
average of the component-wise ESS, not even for the conjugate cases of Section 2.1. For example, for normal
data with known variance s2 = 100 and a mixture prior for the mean θ, p(θ) = 0.5 × N(−2, 22) + 0.5 ×
N(2, 22), the weighted ESS is 0.5×100/4+0.5×100/4 = 25. The other methods give ESSV R = ESSPR =
100/Var(θ) = 100/8 = 12.5, ESSMTM = 0 (because the prior curvature at the mean is 0 for this special
mixture distribution), whereas the predictively consistent ESS is ESSELIR = 13.7.
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3 Applications
3.1 Prior ESS for a proof-of-concept trial using historical control data
We now discuss a recent randomized proof-of-concept phase II trial in which the prior for the parameter in
the control group was informed by historical data. Proof-of-concept trials aim to provide initial evidence
of efficacy for a new treatment. They increasingly use Bayesian approaches for design and analysis (Fisch,
Jones, Jones, Kerman et al. (2015)). Baeten, Baraliakos, Braun, Sieper et al. (2013) describe such a
trial where patients with ankylosing spondylitis, a chronic inflammatory disease, were randomized to the
monoclonal antibody secukinumab (n=24) or to placebo (n=6). The Bayesian primary analysis leveraged
historical placebo data, which allowed the investigators to allocate fewer patients to placebo. This reduced
costs and trial duration and also facilitated recruitment.
The primary efficacy endpoint was binary (response at week six). Eight historical randomized placebo-
controlled clinical trials provided data on the placebo response rate (Table 4). The authors used the
meta-analytic-predictive (MAP) approach (Spiegelhalter et al. (2004), Neuenschwander et al. (2010),
Schmidli, Gsteiger, Roychoudhury, O’Hagan et al. (2014)) to quantify the historical placebo information.
The number of responders in the placebo group of the j-th historical trial is rj |pij ∼ Bin(pij , nj), j =
1, . . . , 8, where pij is the true placebo response rate and nj the number of patients in the placebo group.
Table 4 shows the fairly heterogeneous historical placebo data, with observed response rates in the range
of 12% (trial 7) to 37% (trial 3).
Denoting the placebo response rate in the new trial by pi? and using the log-odds transformation,
θ = log{pi/(1− pi)}, the simplest MAP approach assumes exchangeable parameters, θ?, θ1, . . . , θ8 | µ, τ ∼
N(µ, τ2). Here, the between-trial standard deviation τ characterizes between-trial heterogeneity, that is,
the extent to which the trial parameters can deviate from the mean µ.
The Bayesian MAP analysis requires priors for the parameters µ and τ . For µ, a vague prior is typically
used. However, more care is needed for τ , in particular for few historical trials. For example, the still
popular uniform priors with large upper bound will essentially disregard the historical data because they
put too much probability mass on unrealistically large between-trial standard deviations. Here, we use
a half-normal prior (Spiegelhalter et al. (2004)), which puts most of its probability mass on realistic
between-trial heterogeneities (τ < 2 on the log-odds scale). In the following, we use a N(0, 102) prior for
µ and a half-normal prior with scale 1 for τ . Alternatively, t-priors for µ and half-Cauchy or half-t priors
for τ could be used (Gelman (2006), Polson and Scott (2012)).
Markov chain Monte Carlo (MCMC) have been used to simulate from the posterior distribution
pMAP (pi?) = p(pi? | r1, . . . , r8), which is summarized in Figure 1 and Table 4. It should be noted that
MCMC provides only a simulation sample but no analytic solution for the MAP prior. This complicates
both the calculation of the prior ESS and the Bayesian analysis at the end of the trial. Both issues can
be addressed by approximations to the MAP prior. Baeten et al. (2013) used a single Beta distribution,
but mixture distributions will usually provide much better approximations (Schmidli et al. (2014), Weber
(2019), Weber et al. (2019)). Here, a mixture of two Beta distributions (Table 4) already provides a very
good fit; Figure 1 displays the MAP prior (density plot) and the two-component mixture approximation.
For the design of the new trial, which aims for a smaller placebo group by leveraging the historical infor-
mation, knowing the ESS is important. For the two- and three-component mixture approximation, which
give a very similar fit, the ESSELIR are 36 and 38, considerably larger than the ESS=25 from a single
Beta approximation. Of note, the predictively inconsistent ESSV R is 26 for all approximations, whereas
the ESSMTM for the single Beta and the two mixture approximations are 26, 57, and 91, respectively.
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3.2 Posterior ESS for hierarchical subgroup analyses
The aim of this section is to use effective sample sizes to quantify the gain of information for hierarchical
subgroup analyses. Hierarchical models enable sharing information across similar but non-overlapping
subgroups, which can be particularly helpful for small subgroups.
We use the phase II trial by Chugh, Wathen, Maki, Benjamin et al. (2009) who assessed the effect
of imatinib in ten histological subtypes of sarcoma. The data are shown in Table 5: 179 patients were
available for analysis, with sample sizes ranging from 2 to 29 for the ten subtypes. Observed response
rates for clinical benefit response (CBR) varied from 0% for subtypes 2 and 9 to 24% for subtype 5.
The trial design (Thall, Wathen, Bekele, Champlin et al. (2003)) was based on a standard hierarchical
model, which exploits the anticipated similarity of responses for the 10 subtypes. Robust extensions of
this standard model have been discussed by Leon-Nevelo, Bekele, Mu¨ller, Quintana et al. (2012) and
Neuenschwander, Wandel, Roychoudhury, Bailey (2015). In the sequel, ESSELIR for each subgroup will
be given for the full exchangeability model and three robust extensions.
For binomial data, rj |pij ∼ Bin(pij , nj), a convenient hierarchical model assumes a normal random-
effects distribution for the subtype-specific log-odds parameters θj = log(pij/(1 − pij)), j = 1 . . . 10, i.e.,
θj |µ, τ ∼ N(µ, τ2). The following prior distributions will be used: a vague normal distribution with mean
0 and standard deviation 2 for µ, and a half-normal distribution with scale parameter 1 for τ ; the 95%-
interval of the latter is (0.03,2.24), which covers very small to very large between-subtype heterogeneity
on the log-odds scale. In addition, we use three robust mixture models, assuming the first component as
θj |µ, τ ∼ N(µ, τ2) (with priors as above) and the second component as θj ∼ N(0, 22) for all subgroups.
For each subgroup, mixture weights will be 0.9/0.1, 0.75/0.25, or 0.5/0.5. The four models will be denoted
by (HM-100) for the full exchangeability model and HM-90, HM-75, HM-50 for the three mixture models.
Here, we are interested in the ESS relative to parallel binomial experiments for each subtype, for
which the Fisher information is iF (θj) = exp(θj)/{1 + exp(θj)}2. The MCMC posterior distributions
p(θj |r1, . . . , r10) have been approximated by a mixture of four Beta distributions.
For the four models, Table 5 shows ESSELIR for the response rate in each subgroup. Of course, the
information gain relative to the subgroup sample sizes nj is the largest for the full exchangeability model
(HM-100), with ESS between 54 and 78. On the other hand, the ESS for the robust mixture extensions
can be considerably smaller (in particular for model HM-50) but are still much larger than the subgroup
sample sizes nj .
The results show that even under robust borrowing hierarchical model analyses for subgroups can lead
to substantive information gains compared to stratified analyses. Finally, it should be noted that for the
full exchangeability model, the posterior mixture weights increase for all subtypes, which justifies the full
exchangeability design used in the actual trial (Thall et al. (2003)).
4 Discussion
Modern drug and health-care development tend towards better use of the evidence, which involves using
multiple data sources via meta-analytic methods (21st Century Cures Act (2015), European Commission
(2014), European Medicines Agency (2013, 2018), FDA (2004, 2013, 2018)).
In this regard, the effective sample size (ESS) of trial-external information, which contributes to the
inference in the actual trial, is an important metric. Various methods to obtain the ESS have been
discussed recently. They are similar in that they relate the available information (formally the prior
or posterior precision) to the Fisher information. Yet the methods can give surprisingly different ESS.
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We have shown that the expected local-information-ratio ESSELIR addresses the limitations of current
methods. Importantly, it is predictively consistent and thus correctly quantifies the amount of information
as an equivalent number of observations.
Our focus has been on one-dimensional parameters. Clearly, many applied problems involve more than
one parameter, for which effective sample sizes of individual parameters (or even parameter vectors) are
of interest; for ESSMTM in such settings, see Morita, Thall, Mu¨ller (2012) and Thall, Herrick, Nguyen,
Venier et al. (2014). Finding predictively consistent ESS for such cases requires further research.
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Supporting Information
The on-line material is available at Biometrics website on Wiley Online Library. It contains ESSELIR
functions for mixtures of normal and Beta distributions and code to reproduce the results of Table 3 and
the two applications. Note that the R-package RBesT (Weber (2019), Weber et al. (2019)) is required.
A
A.1 Information i(p(θ)) of a mixture distribution
If the prior (or posterior distribution) is a mixture distribution with K components, p(θ) =
∑K
j=1 wjpj(θ),
its information is
i(p(θ)) = −d2θ log p(θ)
=
1
p2(θ)
 K∑
j=1
wjpj(θ)dθ log pj(θ)
2
− 1
p(θ)
K∑
j=1
wjpj(θ)
[{dθ log pj(θ)}2 + d2θ log pj(θ)]
Here, dθ and d
2
θ denote the first and second derivative, respectively.
A.2 Fitting mixture distributions
Various procedures are available for fitting mixture distributions, for example the mixfit and automixfit
functions in the R-package RBesT (Weber (2019), Weber et al. (2019)), or SAS PROC FMM (2014).
The former has been used to fit the prior and posterior distributions of the applications in Section 3.
A.3 R-function for the ESS of a mixture of Normal or Beta distributions
ess_normmix = function(normmix,
iF.theta = function(x) return(1),
n.sim = 1e6) {
# normmix: k-component mixture distribution, a list with k elements,
each a 3-vector (weight, mean, standard deviation)
# iF.theta: the function returning the Fisher information
# n.sim: number of simulations to obtain the ESS empirically
K = length(normmix)
w = sapply(normmix, function(e) e[1])
mn = sapply(normmix, function(e) e[2])
sd = sapply(normmix, function(e) e[3])
# simulation from mixture distribution
mixcomp = sample( x= 1:K, size = n.sim, replace = TRUE, prob = w )
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theta = rnorm(n.sim, mn[mixcomp], sd[mixcomp])
# 2nd derivates (Appendix 1)
M = 0
for (k in 1:K) { M = M + w[k] * dnorm(theta, mn[k], sd[k])}
sum1 = 0; sum2 = 0
for (k in 1:K) {
sum1=sum1+w[k]*dnorm(theta,mn[k],sd[k])*(-(theta- mn[k])/sd[k]^2)
sum2=sum2+w[k]*dnorm(theta, mn[k], sd[k])*((theta-mn[k])^2/sd[k]^4-1/sd[k]^2)
}
DlogM2 = (-sum1^2/M^2+sum2/M)/iF.theta(theta)
ESS = mean(-DlogM2)
return(ESS)
}
ess_betamix = function(betamix,
iF.theta = function(x) return(1/x/(1-x)),
n.sim = 1e6) {
# betamix: k-component mixture distribution, a list with k elements,
each a 3-vector (weight, a, b)
# iF.theta: the function returning the Fisher information
# n.sim: number of simulations to obtain the ESS empirically
K = length(betamix)
w = sapply(betamix, function(e) e[1])
a = sapply(betamix, function(e) e[2])
b = sapply(betamix, function(e) e[3])
#simulation from mixture distribution
mixcomp = sample( x = 1:K, size = n.sim, replace = TRUE, prob = w )
theta = rbeta(n.sim, a[mixcomp], b[mixcomp])
# 2nd derivates (Appendix 1)
M = 0
for (k in 1:K) { M = M + w[k] * dbeta(theta,a[k], b[k]) }
sum1 = 0; sum2 = 0
for (k in 1:K) {
sum1 = sum1+w[k]*dbeta(theta, a[k], b[k])*
((a[k] - 1)/theta-(b[k]-1)/(1 - theta))
sum2 = sum2+w[k]*dbeta(theta, a[k], b[k])*
(((a[k]-1)/theta-(b[k]-1)/(1-theta))^2-
((a[k]-1)/theta^2+(b[k]-1)/(1-theta)^2))
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}DlogM2 = (1/M^2*sum1^2-1/M*sum2)/iF.theta(theta)
ESS = mean(DlogM2)
return( ESS )
}
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Table 3: Prior ESS and expected posterior ESS − N for planned sample sizes N = 10, 100, and 1000: for
normal data (variance=100) with Student-t prior and exponential data with Weibull prior (see Section 2.5)
Y |θ ∼ N(θ, 102), θ ∼ Student-t(df)
prior ESS (expected posterior ESS)–N
method N=10 N=100 N=1000
df=2 VR — 36 54 59
MTM 150 88 78 62
MTM.P 150 137 85 62
ELIR 60 60 60 60
df=3 VR 33 48 62 67
MTM 133 110 83 70
MTM.P 133 125 87 70
ELIR 67 67 67 68
df=4 VR 50 57 68 70
MTM 125 112 88 73
MTM.P 125 119 90 73
ELIR 71 72 72 71
df=5 VR 60 63 72 75
MTM 120 112 89 77
MTM.P 120 115 91 77
ELIR 75 75 75 75
df=10 VR 80 80 83 85
MTM 110 107 94 86
MTM.P 110 107 95 86
ELIR 85 85 85 85
df=50 VR 96 96 96 96
MTM 102 101 99 97
MTM.P 102 99 99 97
ELIR 96 96 96 96
Y |θ ∼ Exp(θ), θ ∼Weibull(a, s)
prior ESS (expected posterior ESS)–N
method N=10 N=100 N=1000
a=3 VR 8.6 9.6 10 10
PR 3.6 5.5 6.0 6.2
MTM 7.3 8.2 8.8 9.9
MTM.P 6 6.8 7.7 7.9
ELIR 8 8.0 7.9 8.0
a=5 VR 20 23 26 26
PR 15 19 22 22
MTM 18 20 24 24
MTM.P 20 20 22 23
ELIR 24 24 24 24
a=7 VR 36 41 49 50
PR 32 37 45 46
MTM 33 37 44 48
MTM.P 42 41 44 47
ELIR 48 48 48 48
a=9 VR 58 64 77 84
PR 53 59 73 80
MTM 53 57 69 79
MTM.P 72 69 71 78
ELIR 80 80 80 81
a=11 VR 84 91 111 123
PR 79 86 107 119
MTM 77 82 99 117
MTM.P 110 107 105 116
ELIR 120 120 120 121
a=13 VR 115 123 148 168
PR 110 118 144 164
MTM 106 111 133 158
MTM.P 156 152 146 158
ELIR 168 168 167 166
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Table 4: Historical ankylosing spondylitis data, summaries and mixture approximations of meta-analytic-
predictive(MAP) prior, and ESSELIR
Historical data
23/107 (21%), 12/44 (27%), 19/51 (37%), 9/39 (23%), 39/139 (28%), 6/20 (30%), 9/78 (12%), 10/35 (29%)
MAP prior
mean sd 2.5%-97.5%
0.26 0.084 0.11-0.46
Approximations (single Beta and mixtures)
w1 (a1, b1) w2 (a2, b2) w3 (a3, b3) mean sd 2.5%-97.5% ESSELIR
Beta 1.00 (6.8,19.7) 0.26 0.083 0.11-0.43 26
2-comp Beta 0.66 (16.7,51.1) 0.34 (3.4,9.0) 0.26 0.084 0.11-0.47 36
3-comp Beta 0.62 (6.0,17.7) 0.34 (36.0,110) 0.04 (2.5,4.1) 0.26 0.085 0.11-0.45 38
Table 5: Sarcoma subtype data (number of responders/patients) and ESSELIR for each subtype from hierar-
chical model analyses assuming full exchangeability (HM-100) or robust mixtures with 90, 75, or 50% weight
for exchangeability (HM-90, HM-75, HM-50).
HM-100 HM-90 HM-75 HM-50
Subtype r/n (%) ESS
1. Angiosarcoma 2/15 (13) 65 60 50 36
2. Ewing 0/13 (0) 57 46 36 24
3. Fibrosarcoma 1/12 (8) 60 54 44 31
4. Leiomyosarcoma 6/28 (21) 78 72 64 47
5. Liposarcoma 7/29 (24) 76 68 59 43
6. MFH 3/29 (10) 74 69 59 46
7. Osteosarcoma 5/26 (19) 79 73 64 47
8. MPNST 1/5 (20) 57 48 39 23
9. Rhabdomysarcoma 0/2 (0) 54 43 33 18
10. Synovial 2/20 (15) 72 66 57 42
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Figure 1: Median and 95%-intervals for event rates of historical ankylosing spondylitis trials and MAP
event rate for new trial (left panel), and MAP prior density (solid line) with two-component Beta mixture
approximation (dashed line) (right panel).
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